Benjamin Burnett
Stock Analyst at Wells Fargo
(3.89)
# 715
Out of 5,241 analysts
111
Total ratings
56.47%
Success rate
8.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Benjamin Burnett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMPH Amphastar Pharmaceuticals | Downgrades: Equal-Weight | $30 → $19 | $16.87 | +12.63% | 2 | May 14, 2026 | |
| INSM Insmed | Maintains: Overweight | $177 → $160 | $109.14 | +46.60% | 5 | May 8, 2026 | |
| ALKS Alkermes | Maintains: Overweight | $43 → $44 | $37.48 | +17.40% | 5 | May 6, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $225 → $255 | $227.72 | +11.98% | 5 | May 5, 2026 | |
| CNTA Centessa Pharmaceuticals | Downgrades: Equal-Weight | $35 → $42 | $39.60 | +6.07% | 4 | Apr 20, 2026 | |
| FATE Fate Therapeutics | Maintains: Hold | $5 → $3 | $1.76 | +70.94% | 3 | Mar 6, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Hold | $53 → $49 | $48.41 | +1.22% | 6 | Feb 13, 2025 | |
| BEAM Beam Therapeutics | Maintains: Buy | $66 → $69 | $27.93 | +147.05% | 2 | Sep 11, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $63 → $68 | $28.21 | +141.05% | 7 | Sep 10, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Hold | $4.4 → $4.6 | $2.00 | +130.00% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $58 | $9.58 | +500.21% | 4 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $3.45 | +624.64% | 11 | Sep 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $690 → $780 | $7.27 | +10,629.02% | 2 | Sep 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $51 → $62 | $56.93 | +8.91% | 3 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $95 | $71.47 | +32.92% | 3 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $10 | $3.09 | +223.62% | 4 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $575 → $738 | $568.58 | +29.80% | 5 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $47 | $25.00 | +88.00% | 2 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $13 | $6.77 | +92.02% | 4 | Mar 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $46 | $37.07 | +24.09% | 2 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $49 → $68 | $54.39 | +25.02% | 5 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $20 | $10.50 | +90.48% | 2 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $282 → $305 | $342.58 | -10.97% | 2 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $9 | $5.03 | +78.93% | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $64 | $145.66 | -56.06% | 5 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $94 | $66.86 | +40.59% | 7 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $4.42 | +126.24% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $330 → $360 | $70.62 | +409.77% | 2 | Jun 28, 2021 |
Amphastar Pharmaceuticals
May 14, 2026
Downgrades: Equal-Weight
Price Target: $30 → $19
Current: $16.87
Upside: +12.63%
Insmed
May 8, 2026
Maintains: Overweight
Price Target: $177 → $160
Current: $109.14
Upside: +46.60%
Alkermes
May 6, 2026
Maintains: Overweight
Price Target: $43 → $44
Current: $37.48
Upside: +17.40%
Axsome Therapeutics
May 5, 2026
Maintains: Overweight
Price Target: $225 → $255
Current: $227.72
Upside: +11.98%
Centessa Pharmaceuticals
Apr 20, 2026
Downgrades: Equal-Weight
Price Target: $35 → $42
Current: $39.60
Upside: +6.07%
Fate Therapeutics
Mar 6, 2025
Maintains: Hold
Price Target: $5 → $3
Current: $1.76
Upside: +70.94%
CRISPR Therapeutics AG
Feb 13, 2025
Maintains: Hold
Price Target: $53 → $49
Current: $48.41
Upside: +1.22%
Beam Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $66 → $69
Current: $27.93
Upside: +147.05%
IDEAYA Biosciences
Sep 10, 2024
Maintains: Buy
Price Target: $63 → $68
Current: $28.21
Upside: +141.05%
Allogene Therapeutics
May 14, 2024
Maintains: Hold
Price Target: $4.4 → $4.6
Current: $2.00
Upside: +130.00%
Apr 1, 2024
Maintains: Hold
Price Target: $120 → $58
Current: $9.58
Upside: +500.21%
Sep 15, 2023
Reiterates: Buy
Price Target: $25
Current: $3.45
Upside: +624.64%
Sep 10, 2021
Maintains: Buy
Price Target: $690 → $780
Current: $7.27
Upside: +10,629.02%
May 12, 2026
Maintains: Overweight
Price Target: $51 → $62
Current: $56.93
Upside: +8.91%
May 8, 2026
Maintains: Overweight
Price Target: $86 → $95
Current: $71.47
Upside: +32.92%
May 7, 2026
Maintains: Overweight
Price Target: $8 → $10
Current: $3.09
Upside: +223.62%
May 7, 2026
Upgrades: Overweight
Price Target: $575 → $738
Current: $568.58
Upside: +29.80%
May 6, 2026
Maintains: Overweight
Price Target: $45 → $47
Current: $25.00
Upside: +88.00%
Mar 27, 2026
Maintains: Overweight
Price Target: $27 → $13
Current: $6.77
Upside: +92.02%
Mar 11, 2026
Maintains: Overweight
Price Target: $43 → $46
Current: $37.07
Upside: +24.09%
Mar 10, 2026
Maintains: Overweight
Price Target: $49 → $68
Current: $54.39
Upside: +25.02%
Mar 5, 2026
Maintains: Overweight
Price Target: $23 → $20
Current: $10.50
Upside: +90.48%
Feb 20, 2026
Maintains: Equal-Weight
Price Target: $282 → $305
Current: $342.58
Upside: -10.97%
Dec 18, 2025
Maintains: Overweight
Price Target: $7 → $9
Current: $5.03
Upside: +78.93%
Apr 1, 2025
Maintains: Buy
Price Target: $78 → $64
Current: $145.66
Upside: -56.06%
Jan 24, 2025
Maintains: Buy
Price Target: $90 → $94
Current: $66.86
Upside: +40.59%
Jun 3, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $4.42
Upside: +126.24%
Jun 28, 2021
Upgrades: Buy
Price Target: $330 → $360
Current: $70.62
Upside: +409.77%